68Ga-FAPI PET/MR for Atherosclerosis

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Unknown; Early Phase 1

Conditions: Atherosclerosis

Treatments: Drug: 68Ga-FAPI

Study type: Interventional

Funder types: Other

Identifiers

NCT05036759

PUMCH-FAPI-PET/MR

Details and patient eligibility

About

A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.

Full description

A thin-cap fibroatheroma with a large necrotic core and macrophage infiltration marks the vulnerable plaque. Fibroblast activating protein (FAP) is an active serine protease, which can degrade type I collagen, potentially thinning the fibrous cap. Previous ex vivo analysis of human aortic atheromata revealed that FAP was expressed in atherosclerotic plaques, and higher FAP expression was detected in thin fibrous caps than thick caps. Constitutive Fap deletion in atherosclerosis-prone mice models could reduce plaque formation and improve plaque stability with increased fibrous cap thickness. Thus we speculate that atherosclerotic plaque could be imaged with 68Ga-FAPI PET/MR.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• intracranial or carotid atherosclerosis patients
• signed informed consent

Exclusion criteria

• pregnancy, breastfeeding
• contradictions of MRI
• unstable vital signs

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

68Ga-FAPI, PET/MR

Experimental group

Description:

inject 68Ga-FAPI，and then perform PET/MR

Treatment:

Drug: 68Ga-FAPI